We are live on ! Find out more
RCKT icon

Rocket Pharmaceuticals
RCKT

168 hedge funds and large institutions have $1.46B invested in Rocket Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 77 increasing their positions, 41 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

424% more call options, than puts

Call options by funds: $18.9M | Put options by funds: $3.6M

88% more repeat investments, than reductions

Existing positions increased: 77 | Existing positions reduced: 41

33% more capital invested

Capital invested by funds: $1.1B → $1.46B (+$362M)

29% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 24

2% more funds holding

Funds holding: 164 → 168 (+4)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

8.2% less ownership

Funds ownership: 104.58% → 96.38% (-8.2%)

Holders
168
Holders Change
+4
Holders Change %
+2.44%
% of All Funds
2.7%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
31
Increased
77
Reduced
41
Closed
24
Calls
$18.9M
Puts
$3.6M
Net Calls
+$15.3M
Net Calls Change
+$5.95M

Top Buyers

1
RI
RTW Investments
New York
+$34.7M
2
APM
Avidity Partners Management
Texas
+$28.1M
3
BlackRock
BlackRock
New York
+$20.1M
4
MC
Maverick Capital
Texas
+$15.9M
5
Citadel Advisors
Citadel Advisors
Florida
+$15.4M

Top Sellers

1
TCM
Tang Capital Management
California
-$20.2M
2
Goldman Sachs
Goldman Sachs
New York
-$18.6M
3
DM
Deerfield Management
New York
-$13.9M
4
Morgan Stanley
Morgan Stanley
New York
-$12.2M
5
HM
HealthCor Management
New York
-$7.28M
Name Holding Trade Value Shares
Change 		Change in
Stake
Barclays
51
Barclays
United Kingdom
$3.53M +$560K +30,392 +20%
Renaissance Technologies
52
Renaissance Technologies
New York
$3.11M -$5.91M -321,000 -67%
Nisa Investment Advisors
53
Nisa Investment Advisors
Missouri
$2.8M +$2.6M +141,000 +7,085%
GPCM
54
Granite Point Capital Management
Massachusetts
$2.74M +$368K +20,000 +17%
CA
55
Cornerstone Advisory
Maryland
$2.68M +$2.52M +136,763 New
Citigroup
56
Citigroup
New York
$2.63M -$3.73M -202,411 -60%
Swiss National Bank
57
Swiss National Bank
Switzerland
$2.58M +$562K +30,500 +30%
CM
58
Caption Management
Oklahoma
$2.54M +$2.39M +130,000 New
SF
59
Synovus Financial
Georgia
$2.52M +$767K +41,661 +48%
ABG
60
Ally Bridge Group
New York
$2.45M -$6.53M -354,330 -74%
NLVP
61
New Leaf Venture Partners
New York
$2.31M +$2.18M +118,242 New
MPAM
62
Monarch Partners Asset Management
Massachusetts
$2.23M +$497K +27,003 +31%
EAM
63
EFG Asset Management
Oregon
$2.19M +$2.07M +112,502 New
Invesco
64
Invesco
Georgia
$2.12M +$1.34M +72,819 +205%
HWAM
65
Hennion & Walsh Asset Management
New Jersey
$1.94M +$754K +40,919 +70%
HighTower Advisors
66
HighTower Advisors
Illinois
$1.81M +$1.2M +65,107 +237%
DekaBank Deutsche Girozentrale
67
DekaBank Deutsche Girozentrale
Germany
$1.72M – – –
RhumbLine Advisers
68
RhumbLine Advisers
Massachusetts
$1.67M +$275K +14,936 +21%
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
69
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
$1.6M +$1.51M +82,000 New
Two Sigma Investments
70
Two Sigma Investments
New York
$1.41M -$4.92M -267,049 -79%
California State Teachers Retirement System (CalSTRS)
71
California State Teachers Retirement System (CalSTRS)
California
$1.35M +$274K +14,895 +28%
CS
72
Credit Suisse
Switzerland
$1.28M +$632K +34,321 +110%
HCA
73
Harbor Capital Advisors
Illinois
$1.27M -$25.8K -1,401 -2%
IBT
74
International Biotechnology Trust
United Kingdom
$1.23M – – –
Manulife (Manufacturers Life Insurance)
75
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1.18M +$58.8K +3,192 +6%
1 2
3
4 5

RCKT Hedge Fund Activity: Q4 2022 in Review

168 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q4 2022, worth a combined $1.46B — up 33% from $1.1B a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new RCKT positions and 24 closed out — a net gain of 7 holders — while 77 added to existing stakes and 41 trimmed.

The largest buyer was RTW Investments, adding an estimated $34.7M. The largest seller was Tang Capital Management, exiting entirely with an estimated $20.2M sold.

  • 168 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q4 2022, up from 164 in Q3 2022.
  • Funds reported $1.46B of Rocket Pharmaceuticals stock for Q4 2022, up 33% quarter-over-quarter.
  • 31 funds opened new Rocket Pharmaceuticals positions in Q4 2022 and 24 closed out, a net change of +7 holders.
  • The largest Rocket Pharmaceuticals buyer in Q4 2022 was RTW Investments, an estimated $34.7M added.
  • The largest Rocket Pharmaceuticals seller in Q4 2022 was Tang Capital Management, an estimated $20.2M sold.

Based on aggregated 13F filings for Q4 2022.